RUNX1 mutations are consistently associated with a poor prognosis, contributing to lower rates of complete remission (CR), leukemia-free survival (LFS), and overall survival (OS) compared to wild-type RUNX1 AML [3,6,8,11,12,13]. This evidence concerns the gene RUNX1 and leukemia.